The 20Sense Report

Each quarter, we publish rigorous analysis and evidence-based insights that elevate the Canadian pharmaceutical and healthcare conversation by sharing innovative ideas, best practices, challenges, and opportunities.

Understanding Health Canada's Accelerated Drug Approval Pathways
Timely and equitable drug access in Canada
20Sense Issue 30
20Sense Issue 29: understanding patient registries in Canada
20Sense Issue 28: Change makers in Canadian specialty healthcare
20Sense Issue 27: artificial intelligence and specialty healthcare in Canada
20Sense Issue 26: has managed access arrived in Canada?
20Sense Issue 24: REAL-WORLD DATA FROM PATIENT SUPPORT PROGRAMS IN CANADA:
Issue 20: specialty medicine and private payers
Issue 19: Do better? yes, we can
issue 18: Oncology treatment today
Issue 17: Rare diseases and conditions in Canada
Issue 16: Outcomes-based agreements in Canada
Issue 15: The biologic plot thickens
Issue 14: From patients for patients
Issue 13: behind the scenes of a pandemic
Issue 12: Data surge ahead
Issue 11: Patient support programs; a tsunami is rolling in
Issue 10: At the heart of it all; the specialty pharma patient
Issue 9: Are we ready to put health outcomes data to work?
Issue 8: The innovation vs sustainability conundrum
Issue 7: Wanted: more and better specialty data
Issue 6: Patients are talking. Are we listening?
Issue 5: A broken system: the ongoing saga of originator biologics and biosimilars
Issue 4: Oncology medications just got simpler…or did they?
Issue 3: Biosimilars and Patient Support, a Must-Have Combination
Issue 2: The Hidden Value of Patient Support Programs
Issue 1: Joint Value Creation, Innovation and Operational Excellence Required
20Sense Back to Basics: Specialty Pharmaceuticals & Patient Support Programs

Thanks to The 20Sense Report sponsors, supporting independently researched content and working together to provide value and transparency within Canada’s specialty pharmaceutical industry.